BGB-A317-ZW25-101

Completed

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Beigene Study ID info

BGB-A317-ZW25-101

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20210237

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents